Antibiotic treatment for the sexual partner of women with Bacterial Vaginosis (Protocol)
Abstract. Bacterial vaginosis (BV) is an infection that has a prevalence between 10% to 50% worlwide. BV results in an imbalance of the normal vaginal flora. Microorganisms associated with BV have been isolated from the normal flora of the male genital tract, and their presence could be related to t...
- Autores:
-
Viveros Carreño, David Andrés
Sierra Barrios, Eloisa Mercedes
- Tipo de recurso:
- Trabajo de grado de pregrado
- Fecha de publicación:
- 2016
- Institución:
- Universidad Nacional de Colombia
- Repositorio:
- Universidad Nacional de Colombia
- Idioma:
- spa
- OAI Identifier:
- oai:repositorio.unal.edu.co:unal/58852
- Acceso en línea:
- https://repositorio.unal.edu.co/handle/unal/58852
http://bdigital.unal.edu.co/55847/
- Palabra clave:
- 61 Ciencias médicas; Medicina / Medicine and health
Sexual partners
Bacterial vaginosis
Treatment
Compañeros sexuales
Vaginosis bacteriana
Tratamiento
- Rights
- openAccess
- License
- Atribución-NoComercial 4.0 Internacional
id |
UNACIONAL2_9dc4646792ca46ade5190f2642c3c0ac |
---|---|
oai_identifier_str |
oai:repositorio.unal.edu.co:unal/58852 |
network_acronym_str |
UNACIONAL2 |
network_name_str |
Universidad Nacional de Colombia |
repository_id_str |
|
dc.title.spa.fl_str_mv |
Antibiotic treatment for the sexual partner of women with Bacterial Vaginosis (Protocol) |
title |
Antibiotic treatment for the sexual partner of women with Bacterial Vaginosis (Protocol) |
spellingShingle |
Antibiotic treatment for the sexual partner of women with Bacterial Vaginosis (Protocol) 61 Ciencias médicas; Medicina / Medicine and health Sexual partners Bacterial vaginosis Treatment Compañeros sexuales Vaginosis bacteriana Tratamiento |
title_short |
Antibiotic treatment for the sexual partner of women with Bacterial Vaginosis (Protocol) |
title_full |
Antibiotic treatment for the sexual partner of women with Bacterial Vaginosis (Protocol) |
title_fullStr |
Antibiotic treatment for the sexual partner of women with Bacterial Vaginosis (Protocol) |
title_full_unstemmed |
Antibiotic treatment for the sexual partner of women with Bacterial Vaginosis (Protocol) |
title_sort |
Antibiotic treatment for the sexual partner of women with Bacterial Vaginosis (Protocol) |
dc.creator.fl_str_mv |
Viveros Carreño, David Andrés Sierra Barrios, Eloisa Mercedes |
dc.contributor.author.spa.fl_str_mv |
Viveros Carreño, David Andrés Sierra Barrios, Eloisa Mercedes |
dc.contributor.spa.fl_str_mv |
Amaya Guio, Jairo Grillo Ardila, Carlos Fernando |
dc.subject.ddc.spa.fl_str_mv |
61 Ciencias médicas; Medicina / Medicine and health |
topic |
61 Ciencias médicas; Medicina / Medicine and health Sexual partners Bacterial vaginosis Treatment Compañeros sexuales Vaginosis bacteriana Tratamiento |
dc.subject.proposal.spa.fl_str_mv |
Sexual partners Bacterial vaginosis Treatment Compañeros sexuales Vaginosis bacteriana Tratamiento |
description |
Abstract. Bacterial vaginosis (BV) is an infection that has a prevalence between 10% to 50% worlwide. BV results in an imbalance of the normal vaginal flora. Microorganisms associated with BV have been isolated from the normal flora of the male genital tract, and their presence could be related to the recurrence of BV after antibiotic treatment. Therefore, the treatment of sexual partners could decrease the recurrence of infection and possibly the burden of the disease. The objective of the revision was to assess the effectiveness in women and the safety in men of concurrent antibiotic treatment for the sexual partners of women treated for BV. Seven RCTs (1026 participants) met our inclusion criteria, and pharmaceutical industry funded four of these trials. Based on high quality evidence, antibiotic treatment does not increase the rate of clinical or symptomatic improvement in women during the first week (risk ratio (RR) 0.99, 95% confidence interval (CI) 0.96 to 1.03; RR 1.06, 95% CI 1.00 to 1.12, respectively), between the first and fourth week (RR 1.02, 95% CI 0.94 to 1.11; RR 0.93, 95% CI 0.84 to 1.03, respectively) or after the fourth week (RR 0.98, 95% CI 0.90 to 1.07; RR 1.03, 95% CI 0.90 to 1.17, respectively). With low quality evidence antibiotic treatment does not led to a lower recurrence during the first and fourth week (RR 1.28, 95% CI 0.68 to 2.43) or after the fourth week of treatment (RR 1.00, 95% CI 0.67 to 1.52) in women, but increases the frequency of adverse events reported by sexual partners (RR 2.55, 95% CI 1.55 to 4.18). |
publishDate |
2016 |
dc.date.issued.spa.fl_str_mv |
2016-10-01 |
dc.date.accessioned.spa.fl_str_mv |
2019-07-02T14:54:59Z |
dc.date.available.spa.fl_str_mv |
2019-07-02T14:54:59Z |
dc.type.spa.fl_str_mv |
Trabajo de grado - Pregrado |
dc.type.driver.spa.fl_str_mv |
info:eu-repo/semantics/bachelorThesis |
dc.type.version.spa.fl_str_mv |
info:eu-repo/semantics/acceptedVersion |
dc.type.coar.spa.fl_str_mv |
http://purl.org/coar/resource_type/c_7a1f |
dc.type.content.spa.fl_str_mv |
Text |
dc.type.redcol.spa.fl_str_mv |
http://purl.org/redcol/resource_type/TP |
format |
http://purl.org/coar/resource_type/c_7a1f |
status_str |
acceptedVersion |
dc.identifier.uri.none.fl_str_mv |
https://repositorio.unal.edu.co/handle/unal/58852 |
dc.identifier.eprints.spa.fl_str_mv |
http://bdigital.unal.edu.co/55847/ |
url |
https://repositorio.unal.edu.co/handle/unal/58852 http://bdigital.unal.edu.co/55847/ |
dc.language.iso.spa.fl_str_mv |
spa |
language |
spa |
dc.relation.spa.fl_str_mv |
http://www.cochrane.org/CD011701/STI_antibiotic-treatment-sexual-partners-women-bacterial-vaginosis |
dc.relation.ispartof.spa.fl_str_mv |
Universidad Nacional de Colombia Sede Bogotá Facultad de Medicina Departamento de Obstetricia y Ginecología Departamento de Obstetricia y Ginecología |
dc.relation.references.spa.fl_str_mv |
Viveros Carreño, David Andrés and Sierra Barrios, Eloisa Mercedes (2016) Antibiotic treatment for the sexual partner of women with Bacterial Vaginosis (Protocol). Otra thesis, Universidad Nacional de Colombia - Sede Bogotá. |
dc.rights.spa.fl_str_mv |
Derechos reservados - Universidad Nacional de Colombia |
dc.rights.coar.fl_str_mv |
http://purl.org/coar/access_right/c_abf2 |
dc.rights.license.spa.fl_str_mv |
Atribución-NoComercial 4.0 Internacional |
dc.rights.uri.spa.fl_str_mv |
http://creativecommons.org/licenses/by-nc/4.0/ |
dc.rights.accessrights.spa.fl_str_mv |
info:eu-repo/semantics/openAccess |
rights_invalid_str_mv |
Atribución-NoComercial 4.0 Internacional Derechos reservados - Universidad Nacional de Colombia http://creativecommons.org/licenses/by-nc/4.0/ http://purl.org/coar/access_right/c_abf2 |
eu_rights_str_mv |
openAccess |
dc.format.mimetype.spa.fl_str_mv |
application/pdf |
institution |
Universidad Nacional de Colombia |
bitstream.url.fl_str_mv |
https://repositorio.unal.edu.co/bitstream/unal/58852/1/1032453866_1065578098.2016.pdf https://repositorio.unal.edu.co/bitstream/unal/58852/2/1032453866_1065578098.2016.pdf.jpg |
bitstream.checksum.fl_str_mv |
17ff87941dad07e5547bb36f8d5609de e36a64da8834113c03ca3c57bbea15c3 |
bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 |
repository.name.fl_str_mv |
Repositorio Institucional Universidad Nacional de Colombia |
repository.mail.fl_str_mv |
repositorio_nal@unal.edu.co |
_version_ |
1814089214106533888 |
spelling |
Atribución-NoComercial 4.0 InternacionalDerechos reservados - Universidad Nacional de Colombiahttp://creativecommons.org/licenses/by-nc/4.0/info:eu-repo/semantics/openAccesshttp://purl.org/coar/access_right/c_abf2Amaya Guio, JairoGrillo Ardila, Carlos FernandoViveros Carreño, David Andrésc21e0e1f-59d3-4555-a9d7-30712bff7e80300Sierra Barrios, Eloisa Mercedesb587b1b4-53e8-4e0e-8b02-3aba5dff30b13002019-07-02T14:54:59Z2019-07-02T14:54:59Z2016-10-01https://repositorio.unal.edu.co/handle/unal/58852http://bdigital.unal.edu.co/55847/Abstract. Bacterial vaginosis (BV) is an infection that has a prevalence between 10% to 50% worlwide. BV results in an imbalance of the normal vaginal flora. Microorganisms associated with BV have been isolated from the normal flora of the male genital tract, and their presence could be related to the recurrence of BV after antibiotic treatment. Therefore, the treatment of sexual partners could decrease the recurrence of infection and possibly the burden of the disease. The objective of the revision was to assess the effectiveness in women and the safety in men of concurrent antibiotic treatment for the sexual partners of women treated for BV. Seven RCTs (1026 participants) met our inclusion criteria, and pharmaceutical industry funded four of these trials. Based on high quality evidence, antibiotic treatment does not increase the rate of clinical or symptomatic improvement in women during the first week (risk ratio (RR) 0.99, 95% confidence interval (CI) 0.96 to 1.03; RR 1.06, 95% CI 1.00 to 1.12, respectively), between the first and fourth week (RR 1.02, 95% CI 0.94 to 1.11; RR 0.93, 95% CI 0.84 to 1.03, respectively) or after the fourth week (RR 0.98, 95% CI 0.90 to 1.07; RR 1.03, 95% CI 0.90 to 1.17, respectively). With low quality evidence antibiotic treatment does not led to a lower recurrence during the first and fourth week (RR 1.28, 95% CI 0.68 to 2.43) or after the fourth week of treatment (RR 1.00, 95% CI 0.67 to 1.52) in women, but increases the frequency of adverse events reported by sexual partners (RR 2.55, 95% CI 1.55 to 4.18).Resumen. La vaginosis bacteriana es una infección muy frecuente, con una prevalencia que varía entre el 10% y el 50%. Los microorganismos asociados con la VB han sido aislados de la flora normal del tracto masculino y su presencia podría estar relacionada con la recurrencia de la infección luego del tratamiento. De esta manera, el tratamiento a la pareja sexual podría ofrecer las ventajas de disminuir la recurrencia de la infección, romper la cadena de infección y posiblemente disminuir la carga de la enfermedad. El objetivo de la revisión fue Determinar la efectividad y seguridad del tratamiento antibiótico concurrente a la pareja sexual de mujeres tratadas para VB. Siete Ensayos clínicos controlados (1026 participantes) cumplieron los criterios de inclusión, cuatro de ellos fueron patrocinados por la industria. Encontramos con evidencia de alta calidad que el tratamiento antibiótico no incrementa la tase de mejora clínica o sintomática durante la primera semana (RR 0.9, IC 95% 0.96 a 1.03; RR 1.06, IC 95% 1.00 a 1.12 respectivamente), entre la primer y cuarta semana (RR 1.02, IC 95% 0.94 a 1.11; RR 0.93, IC 95% 0.84 a 1.03 respectivamente) o después de la cuarta semana (RR 0.98, IC 95% 0.90 a 1.07; RR 1.03 con IC 95% 0.90 a 1.17 respectivamente). Con calidad de evidencia baja el tratamiento antibiótico no llevó a una menor tasa de recurrencia durante la primer y cuarta semana (RR 1.28, IC 95% 0.68 a 2.43) o después de la cuarta semana de tratamiento (RR 1.00, IC 95% 0.67 a 1.52) pero incrementó la frecuencia de eventos adversos reportados por los compañeros sexuales (RR 2.55, IC 1.55 a 4.18).Otraapplication/pdfspahttp://www.cochrane.org/CD011701/STI_antibiotic-treatment-sexual-partners-women-bacterial-vaginosisUniversidad Nacional de Colombia Sede Bogotá Facultad de Medicina Departamento de Obstetricia y GinecologíaDepartamento de Obstetricia y GinecologíaViveros Carreño, David Andrés and Sierra Barrios, Eloisa Mercedes (2016) Antibiotic treatment for the sexual partner of women with Bacterial Vaginosis (Protocol). Otra thesis, Universidad Nacional de Colombia - Sede Bogotá.61 Ciencias médicas; Medicina / Medicine and healthSexual partnersBacterial vaginosisTreatmentCompañeros sexualesVaginosis bacterianaTratamientoAntibiotic treatment for the sexual partner of women with Bacterial Vaginosis (Protocol)Trabajo de grado - Pregradoinfo:eu-repo/semantics/bachelorThesisinfo:eu-repo/semantics/acceptedVersionhttp://purl.org/coar/resource_type/c_7a1fTexthttp://purl.org/redcol/resource_type/TPORIGINAL1032453866_1065578098.2016.pdfapplication/pdf1852999https://repositorio.unal.edu.co/bitstream/unal/58852/1/1032453866_1065578098.2016.pdf17ff87941dad07e5547bb36f8d5609deMD51THUMBNAIL1032453866_1065578098.2016.pdf.jpg1032453866_1065578098.2016.pdf.jpgGenerated Thumbnailimage/jpeg5098https://repositorio.unal.edu.co/bitstream/unal/58852/2/1032453866_1065578098.2016.pdf.jpge36a64da8834113c03ca3c57bbea15c3MD52unal/58852oai:repositorio.unal.edu.co:unal/588522023-03-29 23:09:31.719Repositorio Institucional Universidad Nacional de Colombiarepositorio_nal@unal.edu.co |